Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease (CoNR)
Cross-over Randomized Controlled Trial of Coenzyme Q10 or Nicotinamide Riboside in Chronic Kidney Disease
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
This PHASE2 trial investigates Chronic Kidney Disease and Frailty and is currently completed. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Feb 2023 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jan 2021 — Dec 2021 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jan 2019 — Dec 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Washington
For direct contact, visit the study record on ClinicalTrials.gov .